Gilead Sciences has agreed to acquire US based biotech firm Ouro Medicines in a deal valued at up to 2.18 billion dollars, gaining access to a promising antibody based treatment originally licensed from China’s Keymed Biosciences. The transaction highlights the growing importance of
A prominent life scientist with deep ties to US research institutions has shifted his academic base to China, highlighting a growing trend of talent movement in global science. Shu Xiaokun, known for his work in advanced biological imaging and molecular tools, has returned
Major international pharmaceutical companies are accelerating their expansion in China, signaling a strategic shift toward localized production as global supply chains become more fragmented. AstraZeneca has announced plans to establish new drug manufacturing facilities in Guangzhou and Shanghai, alongside a dedicated innovation centre
Growing reliance on China’s pharmaceutical supply chain is raising concerns among US policymakers, who warn that dependence on foreign sources for critical drug ingredients could pose long term risks to healthcare security. Lawmakers are increasingly focused on how China has expanded its role
AstraZeneca is deepening its presence in China’s fast growing biotech sector with plans to build a new cell therapy facility in Shanghai, reinforcing its long term commitment to advanced medical innovation in the region. The investment forms part of a broader expansion strategy
China’s contract drug manufacturing industry is facing growing uncertainty as United States pharmaceutical companies accelerate efforts to bring production back onshore and restructure global supply chains. The shift reflects broader geopolitical tensions and strategic concerns around dependency on overseas manufacturing, particularly in critical
Researchers in China have developed an experimental technique that could significantly extend how long organs remain viable for transplantation, potentially reshaping the global organ transplant system. According to a peer reviewed study published in the Journal of Medical Devices, the method allows organs
China has approved its first implantable brain computer interface system, marking a major step in the country’s expanding neurotechnology sector. The device was developed by Neuracle Medical Technology and is designed to help patients with spinal cord injuries regain control of hand movements.
US pharmaceutical giant Eli Lilly has announced plans to invest an additional 3 billion US dollars in China over the next decade, reinforcing its long term commitment to one of the world’s fastest growing healthcare markets. The new investment will focus on strengthening
Mainland Chinese investors are increasingly fueling momentum in Hong Kong listed biotechnology and pharmaceutical companies following a recent adjustment to the Stock Connect southbound trading list. The update now allows mainland investors to trade shares in more than a dozen additional biotech firms
